Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study

Lichao Fan; Chang Liu; Na Li; Huan Liu; Ye Gu; Yongyu Liu; Yu Chen

Fifty-three patients (96·36%) received antiviral therapy for a median time of 14 days (IQR 12-18 days), while two patients (3·64%) were not administered antiviral drugs (one was a pregnant woman and the other had asymptomatic infection). Among those who received antiviral drugs, 45 were in the mild group (95·74% of this group); their median treatment time was 14 days (IQR 12-17 days) and 17 of them (37·78%) were treated with umifenovir, 17 (37·78%) with umifenovir + lopinavir/ritonavir, and five (11.11%) with lopinavir/ritonavir. Moreover, all eight patients in the severe group received antiviral drugs, with a median treatment time of 17·5 days (IQR 11-19·25 days). Four patients in the severe groups (50%) were treated with lopinavir/ritonavir, three (37·50%) with umifenovir + lopinavir/ritonavir, and one (12·50%) with umifenovir. Twenty-nine patients (52·72%) were treated with antibiotics for a median time of 10 days (IQR 8·5-15); 19 of these 29 patients (65·52%) were treated with moxifloxacin while three (10·34%) received linezolid. Among the patients treated with antibiotics, 21 were in the mild group (44·68% of this group); their median treatment time was 13·5 days (IQR 5·75-9·25 days), with 15 (71·42%) treated with moxifloxacin and two (9·52%) receiving carrimycin. The remaining antibiotic recipients comprised all eight patients in the severe group (100%), with a median treatment time of 9 days (IQR 9·75-15·25); four patients (50%) were treated with moxifloxacin and two (25%) with linezolid. Seven patients (12·72%) were treated with glucocorticoids, 20 (36·36%) received recombinant human interferon alpha-1b, and nine (16·36%) were treated with thymalfasin (Figures 1-3 ).